Keywords: novartis, exelon, cleared, dementia, ad, fda, swiss

Novartis' Exelon cleared for dementia AD by US FDA

Article | 22 May 2006

Print This

Swiss drug major Novartis says that its drug candidate Exelon (rivastigmine tartrate) has received a favorable opinion from the Peripheral ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in